Cipla Limited has announced the successful conclusion of a routine current Good Manufacturing Practices (cGMP) and Pre-Approval Inspection (PAI) at its manufacturing facility in Verna, Goa. The inspection, conducted from April 6 to April 17, 2026, resulted in the issuance of two inspectional observations in Form 483. The company is actively coordinating with the USFDA to address these findings within the required timeline.
Inspection Overview
The manufacturing facility in Verna, Goa, recently underwent a scheduled assessment by the US Food and Drug Administration (USFDA). This audit served a dual purpose, functioning as both a routine cGMP inspection to verify adherence to quality standards and a Pre-Approval Inspection (PAI) for future product authorizations. The site visit concluded on April 17, 2026.
Outcome and Next Steps
Following the review, the USFDA issued two observations documented in Form 483. While these findings represent areas for improvement, Cipla has reiterated its commitment to regulatory compliance. The company is working closely with the USFDA and has confirmed that it will address these observations comprehensively within the stipulated timeframe to ensure continued operational readiness and quality assurance at the facility.
Source: BSE
